Human BioSystems
Human BioSystems: Human BioSystems to Expand Into Larger Research Facility
Corporate news transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
Human BioSystems to Expand Into Larger Research Facility
Palo Alto, CA – September 25, 2006 – (OTCBB:HBSC) Human BioSystems (“HBS”
or “Company”) announced today that the Company signed a lease to move from
its current research facility in Vicksburg, Michigan to a larger facility
in the same city.
Dr. Luis Toledo, Chief Medical Officer for HBS said that “All of our organ
preservation research studies were done here at our present facility, but
we are looking forward to moving to larger facilities to accommodate
additional equipment that will be needed to conduct our freezing technology
tests on Islet cells and to continue work on organs.”
HBS signed a five year lease to commence occupancy in December of 2006,
after improvements to the space are made to suit the Company’s laboratory
and office needs.
Human BioSystems is a developer of preservation platforms for organs,
platelets and other biomaterials. The Company, which is headquartered in
Palo Alto, California has research facilities in Michigan.
Contact:
Human BioSystems Investor Relations Investor Relations
Harry Masuda Yes International Concept Communications, LLC
CEO Rich Kaiser James D. Caldwell
(650) 323-0943 (800) 631-8127 (727) 447-0514
hmasuda@humanbiosystems.com rich@yesinternational.com jc@conceptcg.com
Certain statements contained herein are “forward-looking” statements (as
such term is defined in the Private Securities Litigation Reform Act of
1995). Because such statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to, results from ongoing research
and development as well as clinical studies, failure to obtain regulatory
approval for the Company’s products, if required, failure to develop a
product based on the Company’s technology, failure of any such products to
compete effectively with existing products, the inability to find a
strategic partner or to consummate a relationship with a potential
strategic partner on acceptable terms, and other factors discussed in
filings made by the Company with the Securities and Exchange Commission
(c)DGAP 28.09.2006
—————————————————————————
Latest News
Latest Reports
Upcoming Events
No Events found